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Abstract
Background: To date, evidence-based recommendations help doctors to manage patients with
heart failure (HF). However, the implementation of these recommendations in primary care is still
problematic as beneficial drugs are infrequently prescribed. The aim of the study was to determine
whether admission to hospital increases usage of beneficial HF medication and if this usage is
maintained directly after discharge.
Methods: The study was conducted from November 2002 until January 2004. In 77 patients
hospitalised with heart failure (HF), the medication prescribed by the referring general practitioner
(GP) and drug treatment directed by the hospital physicians was documented. Information
regarding the post-discharge (14 d) therapy by the GP was evaluated via a telephone interview.
Ejection fraction values, comorbidity and specifics regarding diagnostic or therapeutic intervention
were collected by chart review.
Results:  When compared to the referring GPs, hospital physicians prescribed more ACE-
inhibitors (58.4% vs. 76.6%; p = 0.001) and beta-blockers of proven efficacy in HF (metoprolol,
bisoprolol, carvedilol; 58.4% vs. 81.8%). Aldosterone antagonists were also administered more
frequently in the hospital setting compared to general practice (14.3% vs. 37.7%). The New York
Heart Association classification for heart failure did not influence whether aldosterone antagonists
were administered either in primary or secondary care. Fourteen days after discharge, there was
no significant discontinuity in discharge medication.
Conclusion: Patients suffering from HF were more likely to receive beneficial medication in
hospital than prior to admission. The treatment regime then remained stable two weeks after
discharge. We suggest that findings on drug continuation in different cardiovascular patients might
be considered validated for patients with HF.
Background
To date, evidence-based recommendations help doctors
to manage patients with heart failure (HF) [1-5]. Accord-
ing to these recommendations, ACE-inhibitors (ACEI)
and in case of ACEI intolerance angiotensin receptor
blockers (ARB) represent the gold standard for the treat-
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ment of heart failure in all four degrees according to the
New York Heart Association (NYHA) [6-9]. For beta
blockers (BB), such a beneficial effect is scientifically
proven for only three substances: metoprolol [10], biso-
prolol [11] and carvedilol [12]. In patients with advanced
HF (NYHA III-IV), aldosterone antagonists (AA) might
improve pathology, endothelial function, and reduce the
frequency of hospitalizations and mortality of patients
[13,14].
However, the implementation of these recommendations
in primary care is still problematic. Literature suggests that
all beneficial drug groups mentioned above are infre-
quently prescribed by general practitioners (GPs) [15-20].
The persistence of out-dated treatment conceptions might
be a reason for this phenomenon [21]. Uncertainty in the
diagnosis of HF and a lack of communication between
involved physicians can also influence whether guidelines
are adhered to by GPs [15,22,23].
Prescription recommendations from hospital physicians
after hospital discharge may increase the prescription rates
of beneficial drugs as hospitalization seems to improve
the transformation of general measures by patients with
HF [24]. However, little is known about whether prescrip-
tion recommendations after discharge are evidence-based
and about what happens to HF medication immediately
after discharge when the GP has to discuss the changes
made in hospital with the patient. For the German health
care system this question is notably relevant, because
patients usually leave hospital just with a recommenda-
tion for further treatment and have to see their GP soon
for new prescriptions. Although GPs sometimes discon-
tinue discharge medication for their patients (e.g. acid-
suppressive medications [25]), it seems to be maintained
in patients with a variety of cardiovascular morbidities
[26]. It is not yet known if this also applies to patients
with heart failure – especially for patients with a reduced
left ventricular function. The question of how and to what
extent medications change when HF patients are admitted
to hospital and discharged into the care of GPs has not
been examined.
The aim of the study was to determine whether admission
to hospital increases the usage of beneficial HF medica-
tion and if this usage is maintained directly after dis-
charge. With a focus on patients with reduced left
ventricular function (45% or less), we analysed prescrip-
tion patterns prior to hospital admission, during hospital-
ization and 14 days after discharge.
Methods
From November 2002 until December 2003, patients
with heart failure hospitalised in the Department of Inter-
nal Medicine at the University Hospital in Göttingen were
identified by the responsible doctor, clinical records and
the admission form submitted by the general practitioner.
The survey ended in January 2004.
Inclusion criteria for patients
￿ Informed consent
￿ Documented diagnosis of heart failure for each NYHA
class (not necessarily the reason of admission)
￿ Ejection fraction ≤ 45%, measured by echocardiography
￿ Age >18 years
￿ Sufficient ability to communicate in German.
Exclusion criteria for patients
￿ Short stay in hospital (only one day or less)
￿ Inability to communicate
￿ Consent not given and/or inability to consent
￿ Severe comorbidity (e.g. cancer or terminal renal insuf-
ficiency).
Ascertainment of medications
The medication for each patient was recorded at three
points in time: directly after admission to hospital (medi-
cation prescribed by the GP), at discharge (medication
specified by hospital doctors) and 2 weeks after discharge
(continuation of discharge medication by GP). During
hospitalization, information regarding the medication
prescribed by patients' GP was recorded using a standard-
ised questionnaire. Medication prescribed in hospital was
obtained from the discharge letter. Fourteen days after dis-
charge, each patient was contacted by telephone and the
details of the current medication were recorded. We ascer-
tained that every patient had already seen his GP after dis-
charge from hospital. All drugs were coded according to
the Anatomical Therapeutic Chemical classification sys-
tem (ATC Code). CS, who collected the data during the
entire study period, was trained in several training ses-
sions. Details of the data collection were presented as well
as preliminary results at several conferences with the par-
ticipation of all research fellows of our department.
Collection of clinical characteristics and statistical analysis
Ejection fraction values, comorbidity and specifics regard-
ing diagnostic or therapeutic intervention were collected
by chart review. Comorbidity was classified according to
the International Classification of Diseases. The severity
of disease was graded according to the NYHA classifica-
tion as documented in the clinical records. Data analysisBMC Family Practice 2006, 7:69 http://www.biomedcentral.com/1471-2296/7/69
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was carried out using SPSS 12.0. For differences in pre-
scription rates, McNemar's Test was performed.
Results
Of 1,785 screened patients, 235 patients with HF could be
identified. Hundred-and-fifty-one patients met inclusion
criteria and 91 patients were willing to participate in the
study, 77 patients were analysed (figure 1): 68 men
(88.3%) and 9 women (11.7%). The baseline characteris-
tics are outlined in the table.
As shown in figure 2, beneficial drug prescriptions (ACEI,
BB, AA) as well as diuretics increased significantly during
hospitalization. After discharge, the number of prescrip-
tions did not decrease significantly (figure 2).
There were no significant differences in the use of ARB
between pre-admission, hospitalization and post-dis-
charge. Of the patients without ACEI medication 31.2%
(10 of 32), 44.4% (8 of 18) and 50% (11 of 22) of these
received ARBs before admission, in hospital and 14 days
after discharge, respectively.
Hospital doctors used BB of proven efficacy in HF (meto-
prolol, bisoprolol, carvedilol) more frequently than GPs.
This effect remained at least 14 days after discharge. Dur-
ing hospital treatment, metoprolol, bisoprolol or
carvedilol, which improve the long-term prognosis of HF
patients, represented 94.0% of all prescribed BB. Before
admission, metoprolol, bisoprolol or carvedilol repre-
sented 86.5% of all BB prescriptions and after discharge
this increased to 90.9%.
AA were also prescribed more often in hospital. However,
patients with more severe heart failure according to the
NYHA classification were not necessarily prescribed AA. In
fact, fairly even numbers of patients in each of the NYHA
categories, with a slightly higher prevalence in the NYHA
classifications I and II, received treatment with AA: 42.1%
of Class I and II in-patients obtained AA (16 of 38), while
only 37.5% of patients in Groups III and IV received AA
(13 of 39).
Discussion and Conclusion
ACEI, BB of proven efficacy (metoprolol, bisoprolol,
carvedilol) and AA were used significantly more often by
hospital physicians than by referring GPs. Although
administered more frequently to in-patients, AA were not
prescribed predominantly to severely ill patients contrary
to evidence-based recommendations. However, this
might be due to cogent conditions (e.g. hyperkaliaemia)
that could not be elaborated within our study. Fourteen
days after discharge there was no significant discontinuity
in discharge medication. Most of our patients received
diuretics although they do not fit in the current patho-
physiological model of HF. According to that model,
diminishing the activation of the renine-angiotensin sys-
tem and sympathical activation is thought to be essential
in the treatment of patients with HF. However, possibly
evidence based recommendations underestimate diuretics
since all important studies on HF show the beneficial
effect of ACEI, BB and AA in addition to diuretics.
The two most-striking results of our study are as follows:
1. Compared to hospital doctors, referring GPs prescribed
drugs influencing long-term prognosis relatively infre-
quently – in spite of published recommendations.
2. AA were administered more frequently during hospital
treatments but contrary to treatment guidelines, severely
diseased patients did not preferentially receive this medi-
cation.
Our findings are primarily based on the analysis of pre-
scription patterns and do not take into consideration the
quality of the treatment for a particular patient. Addition-
ally, because of the asymmetrical gender distribution in
Participation in the study [26] Figure 1
Participation in the study [26].BMC Family Practice 2006, 7:69 http://www.biomedcentral.com/1471-2296/7/69
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our sample, our conclusions may not be generally appli-
cable. Whereas fourteen patients declined participation
during the study (figure 1), from all remaining patients (N
= 77) all three HF medications could be obtained. Validity
of medication records might be reduced, because infor-
mation on drug treatment two weeks after discharge was
obtained by telephone. However, we are in line with some
other studies that also collected medication data on basis
of telephone interviews, for example the Valencia study
[27] in which patients were telephoned after discharge.
Moreover, several measures should contribute to the
validity of the data: (1) patients were confronted with a
personal survey on their medication use already in hospi-
tal so that they became familiar with these questions. (2)
Pharmacotherapy of HF patients before admission, in hospital and 14 days after discharge Figure 2
Pharmacotherapy of HF patients before admission, in hospital and 14 days after discharge.
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They were told that they could expect a phone call two
weeks after discharge using similar questions. (3) Difficul-
ties to communicate (e.g. dementia) belonged to the
exclusion criteria so that we only interviewed patients
with an adequate memory and sufficient intelligence. (4)
Patients were told to bring all their medication to the tel-
ephone and to spell the names of the drugs.
According to current literature, the lack of adherence to
discharge recommendations by primary care doctors is at
least partially due to an interface problem between pri-
mary and secondary care. GPs might consider discontinu-
ing drugs prescribed in hospital for primary care patients
(e.g. acid-suppressive medications [24]). However, cardi-
ovascular drugs are maintained by GPs in patients with a
variety of cardiovascular diseases as Harder et al. sug-
gested [25]. Our data might complement these findings
on drug continuation since they also seem to apply for HF
patients with decreased ejection fraction.
In our study, approximately 60% of the outpatients and
almost 80% of in-patients received ACEI. BB were pre-
scribed in about 60% of primary care patients and in 85%
of hospital patients. This is in distinct contrast to a study
of Rutten et al. published in 2003 [28], which found that
Dutch GPs and internists prescribed ACEI and BB much
less frequently (40% GPs vs. 76% internists and 9% vs.
30%, respectively) while AAs (11% vs. 76%) were pre-
scribed at a frequency similar to that found in our study.
While our study included only patients with a left ven-
tricular function of 45% or less, Rutten et al. considered
all types of HF patients and in the case of GP manage-
ment, only those HF patients that were not co-treated by
a cardiologist. In an earlier review [29] on treatment pat-
terns in heart failure in nine European countries, prescrip-
tion rates of ACEI and BB were noticeably lower.
Interface problems are regarded as an important factor for
the continuity of evidence-based medicine [30]. Our
study showed that there was no significant discontinuity
in HF medication in patients discharged from hospital.
Further research is needed to analyse, whether this trend
also applies to the long-term prescription of beneficial
drugs. With regard to the prescription rates seen in our
study, there might still be potential for extended usage of
established drugs in the pharmacotherapy of patients
prior to or without admission to hospital.
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